ASMB Assembly Biosciences Inc
Price (delayed)
$11.04
Market cap
$70.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.89
Enterprise value
$43.16M
Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the
Highlights
ASMB's EPS has surged by 60% year-on-year and by 21% since the previous quarter
Assembly Biosciences's net income has increased by 44% YoY and by 11% QoQ
The company's debt has surged by 57% YoY but it fell by 17% QoQ
ASMB's quick ratio has dropped by 65% year-on-year and by 14% since the previous quarter
The equity has decreased by 38% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of ASMB
Market
Valuations
Earnings
Shares outstanding
6.36M
Market cap
$70.17M
Enterprise value
$43.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$74.77M
Net income
-$40.8M
EBIT
-$40.37M
EBITDA
-$40.18M
Free cash flow
$22.86M
Per share
Balance sheet
Liquidity
EPS
-$6.89
EPS diluted
-$6.89
Free cash flow per share
$3.6
Book value per share
$4.1
Revenue per share
$0
TBVPS
$15.79
Total assets
$100.26M
Total liabilities
$74.26M
Debt
$1.44M
Equity
$26M
Working capital
$56.58M
Debt to equity
0.06
Current ratio
2.36
Quick ratio
2.28
Net debt/EBITDA
0.67
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-34.6%
Return on equity
-121.5%
Return on invested capital
-69.4%
Return on capital employed
-68.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ASMB stock price
How has the Assembly Biosciences stock price performed over time
Intraday
2.13%
1 week
-7.85%
1 month
-12.17%
1 year
-13.62%
YTD
-30.04%
QTD
-30.04%
Financial performance
How have Assembly Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$74.77M
Net income
-$40.8M
Gross margin
N/A
Net margin
N/A
Assembly Biosciences's net income has increased by 44% YoY and by 11% QoQ
Assembly Biosciences's operating income has decreased by 3.8% QoQ
Growth
What is Assembly Biosciences's growth rate over time
Valuation
What is Assembly Biosciences stock price valuation
P/E
N/A
P/B
2.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ASMB's EPS has surged by 60% year-on-year and by 21% since the previous quarter
The price to book (P/B) is 92% higher than the 5-year quarterly average of 1.4 and 12% higher than the last 4 quarters average of 2.4
The equity has decreased by 38% YoY and by 25% from the previous quarter
Efficiency
How efficient is Assembly Biosciences business performance
The ROIC has soared by 70% YoY and by 16% from the previous quarter
The company's return on assets has surged by 64% YoY and by 20% QoQ
The return on equity has declined by 4.4% year-on-year
Dividends
What is ASMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ASMB.
Financial health
How did Assembly Biosciences financials performed over time
The total assets is 35% more than the total liabilities
The total assets has soared by 94% YoY but it has contracted by 13% from the previous quarter
Assembly Biosciences's current ratio has shrunk by 66% YoY and by 14% QoQ
The company's debt is 94% lower than its equity
The debt to equity has soared by 200% YoY and by 20% from the previous quarter
The company's debt has surged by 57% YoY but it fell by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.